SAN DIEGO--(BUSINESS WIRE)--July 6, 2006--AVANIR Pharmaceuticals (NASDAQ:AVNR - News) announced today that it has signed an exclusive agreement with Healthcare Brands International (HBI) to develop and market AVANIR’s docosanol 10% cream (docosanol) as a treatment for cold sores in the European Union, (with the exception of Denmark, Finland, Greece, Italy, and Sweden, all of which are covered by previous license grants from AVANIR) Russia and the Ukraine.
